Merck Gets Priority Review for Ebola Zaire Vaccine
The FDA granted Merck priority review for its V920 vaccine for preventing the disease caused by the Ebola Zaire virus.
The European Medicines Agency accepted a market authorization application for the vaccine for review in March.
The priority review designation “underscores our long-standing partnership with the U.S. government” toward the vaccine’s development and licensure, said Paula Annunziato, vice president of Merck Research Laboratories. The agency is expected to approve the drug on March 14, 2020.